.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XG01_Bortezomib.Bortezomib

Information

Bortezomib is a reversible proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. It is administered parenterally and is FDA-approved for clinical use.

Pharmacokinetics

Healthy adult patients and patients with multiple myeloma, intravenous bolus administration.

References

1. Savelieva, M, et al., & Capdeville, R (2015). Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. European journal of clinical pharmacology 71(6) 663–672. DOI:10.1007/s00228-015-1846-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25939707

2. Hanley, MJ, et al., & Venkatakrishnan, K (2017). Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. Journal of clinical pharmacology 57(9) 1183–1193. DOI:10.1002/jcph.906 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28419486

3. Janssen, JM, et al., & Huitema, ADR (2020). A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical pharmacokinetics 59(2) 207–216. DOI:10.1007/s40262-019-00803-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/31313068

Revisions

• 06/2025 initial generated model